What is KYMR's current stock price?

As of now, KYMR is trading at $61.26, with a daily change of +4.43%.

What are the risks associated with KYMR stock?

KYMR Key risk is its Moderate, .

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

KYMR Stock Analysis & IQ Rating | Kymera Therapeutics

KYMR

Kymera Therapeutics

$61.26

+$2.60 | +4.43%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$ 63.96

MKT CAP

$ 4.39B

52W Low

$ 19.45

VOL

$ 492.96K

P/E Ratio

N/A

AVG VOL

$ 690.65K

RSI

57.59

TREND

Uptrend

KYMR Stock IQ

Login to see Kymera Therapeutics (KYMR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

KYMR Target Price

Login to display

Strengths

KYMR Rewards

Upgraded on attractively valued

KYMR Rewards

Outperform the market

Chart

$59.89 (+2.29%)

$42.63 (+43.70%)

$46.44 (+31.91%)

$43.51 (+40.80%)

1year

6month

3month

1month

KYMR Risk Level

KYMR has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Moderate

LOW

HIGH

KYMR Analysts Opinion

KYMR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

KYMR Analysts Opinion

KYMR Analysts opinion is positive and also has improved from the past 3 months

KYMR Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

63%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

100%

KYMR Street Sentiment

KYMR Street Sentiment is bullish and have positive views on the near-term outlook

KYMR Performance Sentiment

Sentiments overview associated with KYMR events and the stock performance.

63%

32%

Positive

Negative

12 out of 19
events present

6 out of 19
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$61.00

Resistance
Price

$51.92

Current Price Range

$62.89

Show methods +

KYMR Latest Analysis +

Kymera Therapeutics Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript.

Today

$61.26 | +4.43%

Activity

Barclays Maintains Kymera Therapeutics (KYMR) Overweight Recommendation. Fintel reports that on November 5 2025 Barclays maintained coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Overweight recommendation. Analyst Price Forecast Suggests 16.54% Upside

Thu Nov 6, 2025

$61.00 | +1.85%

Rating

HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation. Fintel reports that on November 5 2025 HC Wainwright &. Co. maintained coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Buy recommendation. Analyst Price Forecast Suggests 16.50% Upside

Wed Nov 5, 2025

$59.89 | +0.30%

Rating

Kymera Therapeutics Inc. (NASDAQ:KYMR) Q3 2025 Earnings Call Transcript. Kymera Therapeutics Inc. (NASDAQ:KYMR) Q3 2025 Earnings Call Transcript November 4 2025 Kymera Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.94129 EPS expectations were $-0.72. Operator: Good day everyone. My name is Sophie and I will be your conference operator today. At this time I would like to welcome you to the Kymera [….]

Wed Nov 5, 2025

$59.89 | +0.30%

Earnings

10 Analysts Have This To Say About Kymera Therapeutics. Across the recent three months 10 analysts have shared their insights on Kymera Therapeutics (NASDAQ:) expressing a variety of opinions spanning from ish to bearish.The table below summarizes their recent ratings showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.6400010000310002300000000Analysts have recently evaluated Kymera Therapeutics and provided 12-month price targets. The average ta

Wed Nov 5, 2025

$59.89 | +0.30%

Momentum

Kymera Therapeutics Inc. (KYMR) Reports Q3 Loss Misses Revenue Estimates. Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Tue Nov 4, 2025

$59.91 | +0.32%

Earnings

Kymera Therapeutics GAAP EPS of -$0.94 misses by $0.18 revenue of $2.76M misses by $20.38M.

Tue Nov 4, 2025

$59.91 | +0.32%

Earnings

Kymera Therapeutics Presents New Preclinical Data for KT-579 a First-in-Class Oral IRF5 Degrader at the American College of Rheumatology Annual Meeting. KT-579 a potent selective oral degrader of IRF5 demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA) with activity comparable or superior to approved and clinically active therapiesKT-579 Phase 1 testing expected to begin in early 2026WATERTOWN Mass. Oct. 27 2025 (GLOBE NEWSWIRE) -- (NASDAQ:) a c

Mon Oct 27, 2025

$60.85 | +3.91%

Activity

Potential

Kymera Therapeutics Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release. Kymera Therapeutics (KYMR) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$57.76 | +3.51%

Earnings

BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation. Fintel reports that on October 22 2025 BTIG maintained coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Buy recommendation. Analyst Price Forecast Suggests 10.28% Upside

Wed Oct 22, 2025

$55.80 | -4.32%

Rating

FAQ About KYMR Stock Insights

What is KYMR current stock price?

What are KYMR stock strengths?

What risks are associated with KYMR stock?

When is KYMR next earnings report?

What is KYMR market cap and volume?

What is KYMR's current Stock IQ?

Should I buy KYMR stock right now?

Is KYMR a Strong Buy right now?

What does a 'Strong Buy' rating mean for KYMR?

What does a 'Strong Sell' rating mean for KYMR?

What factors influence KYMR's Stock IQ?

Explore our KYMR Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored KYMR Stock Strategies
Effective Risk Management

FIND US ON

Receive our KYMR Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

KYMR

Kymera Therapeutics

Current Price

$61.26

+$2.60 | +4.43%

52W High

$ 63.96

MKT CAP

$ 4.39B

52W Low

$ 19.45

VOL

$ 492.96K

P/E Ratio

N/A

AVG VOL

$ 690.65K

RSI

57.59

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

KYMR Rewards

Upgraded on attractively valued

KYMR Rewards

Outperform the market

KYMR Stock IQ

Login to unlock Kymera Therapeutics (KYMR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$59.89 (+2.29%)

$42.63 (+43.70%)

$46.44 (+31.91%)

$43.51 (+40.80%)

1year

6month

3month

1month

KYMR Analysts Opinion

KYMR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

KYMR Analysts Opinion

KYMR Analysts opinion is positive and also has improved from the past 3 months

KYMR Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

63%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

50%

100%

KYMR Street Sentiment

KYMR Street Sentiment is bullish and have positive views on the near-term outlook

KYMR Risk Level

KYMR has Moderate risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Moderate

LOW

HIGH

KYMR Performance Sentiment

Sentiments overview associated with KYMR events and the stock performance.

63%

32%

Positive

Negative

12 out of 19
events present

6 out of 19
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$61.00

Resistance
Price

$51.92

Current Price Range

$62.89

Show methods +

KYMR Latest Analysis

Kymera Therapeutics Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript.

Today

$61.26 | +4.43%

Activity

Barclays Maintains Kymera Therapeutics (KYMR) Overweight Recommendation. Fintel reports that on November 5 2025 Barclays maintained coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Overweight recommendation. Analyst Price Forecast Suggests 16.54% Upside

Thu Nov 6, 2025

$61.00 | +1.85%

Rating

HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation. Fintel reports that on November 5 2025 HC Wainwright &. Co. maintained coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Buy recommendation. Analyst Price Forecast Suggests 16.50% Upside

Wed Nov 5, 2025

$59.89 | +0.30%

Rating

Kymera Therapeutics Inc. (NASDAQ:KYMR) Q3 2025 Earnings Call Transcript. Kymera Therapeutics Inc. (NASDAQ:KYMR) Q3 2025 Earnings Call Transcript November 4 2025 Kymera Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.94129 EPS expectations were $-0.72. Operator: Good day everyone. My name is Sophie and I will be your conference operator today. At this time I would like to welcome you to the Kymera [….]

Wed Nov 5, 2025

$59.89 | +0.30%

Earnings

10 Analysts Have This To Say About Kymera Therapeutics. Across the recent three months 10 analysts have shared their insights on Kymera Therapeutics (NASDAQ:) expressing a variety of opinions spanning from ish to bearish.The table below summarizes their recent ratings showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.6400010000310002300000000Analysts have recently evaluated Kymera Therapeutics and provided 12-month price targets. The average ta

Wed Nov 5, 2025

$59.89 | +0.30%

Momentum

Kymera Therapeutics Inc. (KYMR) Reports Q3 Loss Misses Revenue Estimates. Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Tue Nov 4, 2025

$59.91 | +0.32%

Earnings

Kymera Therapeutics GAAP EPS of -$0.94 misses by $0.18 revenue of $2.76M misses by $20.38M.

Tue Nov 4, 2025

$59.91 | +0.32%

Earnings

Kymera Therapeutics Presents New Preclinical Data for KT-579 a First-in-Class Oral IRF5 Degrader at the American College of Rheumatology Annual Meeting. KT-579 a potent selective oral degrader of IRF5 demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA) with activity comparable or superior to approved and clinically active therapiesKT-579 Phase 1 testing expected to begin in early 2026WATERTOWN Mass. Oct. 27 2025 (GLOBE NEWSWIRE) -- (NASDAQ:) a c

Mon Oct 27, 2025

$60.85 | +3.91%

Activity

Potential

Kymera Therapeutics Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release. Kymera Therapeutics (KYMR) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thu Oct 23, 2025

$57.76 | +3.51%

Earnings

BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation. Fintel reports that on October 22 2025 BTIG maintained coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Buy recommendation. Analyst Price Forecast Suggests 10.28% Upside

Wed Oct 22, 2025

$55.80 | -4.32%

Rating

Discover KYMR Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of KYMR. We're here to help you make informed investment decisions today.

FIND US ON

Receive our KYMR Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

KYMR Stock trends

KYMR Stock performance

KYMR Stock analysis

KYMR investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing KYMR

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing KYMR

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

KYMR Stock Analysis & IQ Rating | Kymera Therapeutics

KYMR Stock IQ

KYMR Target Price

KYMR Risk Level

KYMR Analysts Opinion

KYMR Street Sentiment

KYMR Performance Sentiment

Technical Price Levels

Explore our KYMR Stock insights

Receive our KYMR Daily Alerts

KYMR Stock IQ

KYMR Street Sentiment

KYMR Risk Level

Technical Price Levels

Discover KYMR Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of KYMR. We're here to help you make informed investment decisions today.

Receive our KYMR Daily Alerts

KYMR Runner Alarm